| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.51▼ | 2.49▲ | 2.50▲ | 2.68▼ | 2.68▼ |
| MA10 | 2.51▼ | 2.50▲ | 2.57▼ | 2.67▼ | 2.56▼ |
| MA20 | 2.49▲ | 2.58▼ | 2.66▼ | 2.71▼ | 2.52▼ |
| MA50 | 2.51▼ | 2.68▼ | 2.67▼ | 2.55▼ | 2.85▼ |
| MA100 | 2.59▼ | 2.67▼ | 2.70▼ | 2.56▼ | 2.63▼ |
| MA200 | 2.68▼ | 2.72▼ | 2.72▼ | 2.82▼ | 2.81▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.006▲ | -0.003▼ | -0.022▼ | -0.025▼ | 0.038▲ |
| RSI | 52.496▲ | 38.437▼ | 37.979▼ | 42.688▼ | 47.302▼ |
| STOCH | 68.576 | 26.423 | 12.642▼ | 39.558 | 68.283 |
| WILL %R | -36.842 | -78.182▼ | -82.353▼ | -85.052▼ | -54.545 |
| CCI | 21.928 | -24.474 | -71.730 | -220.276▼ | 36.763 |
|
Saturday, September 26, 2026 01:02 PM
AC Immune (NASDAQ:ACIU) reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104.056, an active immunotherapy designed to target aggregated alpha-synuclein in early Parkinson’s ...
|
|
Thursday, September 24, 2026 02:33 AM
Swiss clinical-stage biopharma AC Immune has announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, its randomized, double-blind, placebo-controlled Phase II trial ...
|
|
Wednesday, September 23, 2026 04:00 AM
AC Immune SA (NASDAQ: ACIU) announced positive safety and immunogenicity results through week-100 in Part 1 of VacSYn, a randomized, double-blind, placebo-controlled Phase 2 trial of ACI-7104 in ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 25/09/26 | 2.66 | 2.66 | 2.452 | 2.52 | 323,580 |
| 24/09/26 | 2.85 | 2.85 | 2.66 | 2.66 | 265,287 |
| 23/09/26 | 2.90 | 2.9069 | 2.6689 | 2.83 | 492,823 |
| 22/09/26 | 2.69 | 2.75 | 2.66 | 2.73 | 78,091 |
| 21/09/26 | 2.63 | 2.72 | 2.57 | 2.655 | 109,425 |
| 18/09/26 | 2.69 | 2.8063 | 2.625 | 2.63 | 68,461 |
| 17/09/26 | 2.71 | 2.74 | 2.66 | 2.68 | 93,347 |
| 16/09/26 | 2.68 | 2.73 | 2.61 | 2.65 | 124,399 |
| 15/09/26 | 2.65 | 2.70 | 2.59 | 2.68 | 93,530 |
| 14/09/26 | 2.69 | 2.75 | 2.66 | 2.66 | 111,832 |
|
|
||||
|
|
||||
|
|